文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

单部位双腔与多部位插管对接受静脉-静脉体外膜氧合治疗的COVID-19呼吸衰竭成人患者结局的影响

Outcomes With Single-Site Dual-Lumen Versus Multisite Cannulation for Adults With COVID-19 Respiratory Failure Receiving Venovenous Extracorporeal Membrane Oxygenation.
PubMed 文献 · Crit Care Med · 2023-08-07
一句话结论在COVID-19需VV-ECMO患者中,多部位与单部位双腔插管的90天生存率无差异(49.4% vs 48.9%,p=0.66),不支持任一插管策略更优。

该研究为体外生命支持组织登记数据库的回顾性分析,采用倾向评分匹配(2:1 多部位 vs 单部位双腔)控制混杂,匹配队列纳入170个中心的2,628例患者(多部位1,752例,单部位双腔876例)。主要终点90天生存率两组无差异(49.4% vs 48.9%,p=0.66),出院生存率、ECMO支持时长、插管后住院时长亦无差异。单部位双腔组24小时内拔管比例更高(4% vs 1.9%,p=0.001),但气胸发生率更高(13.9% vs 11%,p=0.03);多部位组插管部位出血、氧合器故障和管路血栓更常见。结论认为这些差异不支持任一插管策略的优越性。

要点

  • 匹配队列中多部位与单部位双腔插管的90天生存率无差异(49.4% vs 48.9%,p=0.66)。
  • 单部位双腔组24小时内拔管比例更高(4% vs 1.9%,p=0.001),但气胸发生率更高(13.9% vs 11%,p=0.03)。
  • 多部位组插管部位出血(6.4% vs 4.7%,p=0.03)、氧合器故障(16.7% vs 13.4%,p=0.03)和管路血栓(5.5% vs 3.4%,p=0.02)更常见。
  • 多部位组24小时ECMO流量更高(4.5 vs 4.1 L/min,p<0.001),90天无ECMO支持天数更多(3.1 vs 2.0 d,p=0.02)。
  • 出院生存率(49.8% vs 48.2%,p=0.44)、ECMO支持时长(17.9 vs 17.1 d,p=0.82)和插管后住院时长(28 vs 27.4 d,p=0.37)两组无差异。

适用人群与场景

  • COVID-19呼吸衰竭接受静脉-静脉体外膜氧合(VV-ECMO)的成人患者,来自体外生命支持组织登记数据库的170个中心。
  • 匹配队列共2,628例(多部位插管1,752例,单部位双腔插管876例);整个队列平均(标准差)年龄48(11)岁,3,909例(71%)为男性;VV-ECMO支持前机械通气中位(四分位距)时间79(113)小时。

研究设计与关键结果

  • 研究设计:体外生命支持组织登记数据库的回顾性分析,采用倾向评分匹配(2:1 多部位 vs 单部位双腔)控制混杂。
  • 主要终点90天生存率:多部位组49.4% vs 单部位双腔组48.9%,p=0.66。
  • 出院生存率:多部位组49.8% vs 单部位双腔组48.2%,p=0.44。
  • ECMO支持时长:多部位组17.9 d vs 单部位双腔组17.1 d,p=0.82。
  • 插管后住院时长:多部位组28 d vs 单部位双腔组27.4 d,p=0.37。
  • 24小时内拔管比例:单部位双腔组4% vs 多部位组1.9%,p=0.001。
  • 24小时ECMO流量:多部位组4.5 L/min vs 单部位双腔组4.1 L/min,p<0.001。
  • 90天无ECMO支持天数:多部位组3.1 d vs 单部位双腔组2.0 d,p=0.02;气胸发生率:单部位双腔组13.9% vs 多部位组11%,p=0.03;插管部位出血:多部位组6.4% vs 单部位双腔组4.7%,p=0.03;氧合器故障:多部位组16.7% vs 单部位双腔组13.4%,p=0.03;管路血栓:多部位组5.5% vs 单部位双腔组3.4%,p=0.02。

证据类型、等级与局限

  • 证据类型:基于体外生命支持组织登记数据库的回顾性分析,采用倾向评分匹配(2:1 多部位 vs 单部位双腔)控制混杂。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,这些发现不支持在COVID-19需VV-ECMO患者中任一插管策略具有优越性。
  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: To determine whether multisite versus single-site dual-lumen (SSDL) cannulation is associated with outcomes for COVID-19 patients requiring venovenous extracorporeal membrane oxygenation (VV-ECMO).

DESIGN: Retrospective analysis of the Extracorporeal Life Support Organization Registry. Propensity score matching (2:1 multisite vs SSDL) was used to control for confounders.

PATIENTS: The matched cohort included 2,628 patients (1,752 multisite, 876 SSDL) from 170 centers. The mean ( sd ) age in the entire cohort was 48 (11) years, and 3,909 (71%) were male. Patients were supported with mechanical ventilation for a median (interquartile range) of 79 (113) hours before VV-ECMO support.

INTERVENTIONS: None.

MEASUREMENTS: The primary outcome was 90-day survival. Secondary outcomes included survival to hospital discharge, duration of ECMO support, days free of ECMO support at 90 days, and complication rates.

MAIN RESULTS: There was no difference in 90-day survival (49.4 vs 48.9%, p = 0.66), survival to hospital discharge (49.8 vs 48.2%, p = 0.44), duration of ECMO support (17.9 vs 17.1 d, p = 0.82), or hospital length of stay after cannulation (28 vs 27.4 d, p = 0.37) between multisite and SSDL groups. More SSDL patients were extubated within 24 hours (4% vs 1.9%, p = 0.001). Multisite patients had higher ECMO flows at 24 hours (4.5 vs 4.1 L/min, p < 0.001) and more ECMO-free days at 90 days (3.1 vs 2.0 d, p = 0.02). SSDL patients had higher rates of pneumothorax (13.9% vs 11%, p = 0.03). Cannula site bleeding (6.4% vs 4.7%, p = 0.03), oxygenator failure (16.7 vs 13.4%, p = 0.03), and circuit clots (5.5% vs 3.4%, p = 0.02) were more frequent in multisite patients.

CONCLUSIONS: In this retrospective study of COVID-19 patients requiring VV-ECMO, 90-day survival did not differ between patients treated with a multisite versus SSDL cannulation strategy and there were only modest differences in major complication rates. These findings do not support the superiority of either cannulation strategy in this setting.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. O'Gara BP, Tung MG, Kennedy KF, et al. Outcomes With Single-Site Dual-Lumen Versus Multisite Cannulation for Adults With COVID-19 Respiratory Failure Receiving Venovenous Extracorporeal Membrane Oxygenation. Crit Care Med. 2023. PMID: 37548506. doi:10.1097/CCM.0000000000006014

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。